Summary & Overview
CPT 81179: ATXN2 (Ataxin 2) Repeat Expansion Testing
CPT code 81179 covers the technical laboratory assay to detect expanded allele sequences in the ATXN2 (ataxin 2) gene. This molecular diagnostic service is clinically important because ATXN2 repeat expansions are associated with neurodegenerative disorders; accurate detection informs diagnostic evaluation, genetic counseling, and care planning. Nationally, growth in genetic testing utilization and the centralization of specialized molecular labs make clear coding for technical components like CPT code 81179 important for claims processing and payment clarity.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes coverage considerations and benchmarks commonly referenced by major commercial insurers and the Medicare program.
Readers will find a concise overview of what CPT code 81179 represents, typical sites of service, commonly reported modifiers, and where this technical component fits within the diagnostic workflow. The report also outlines clinical context for ATXN2 repeat testing and points readers to related coding areas. Data not available in the input for specific payer policies, claim frequency, or reimbursement benchmarks is noted where applicable.
Billing Code Overview
CPT code 81179 describes a technical laboratory test performed by a lab analyst to detect the presence of changes in the gene ataxin 2 (ATXN2), specifically to identify abnormal alleles involving expanded sequences. This service is a molecular genetic diagnostic test focused on detecting repeat expansions in the ATXN2 gene.
Service Type: Genetic testing — molecular diagnostic, technical component
Typical Site of Service: Clinical laboratory or specialized molecular diagnostics laboratory
Clinical & Coding Specifications
Clinical Context
A 48-year-old adult with progressive cerebellar ataxia and a family history of spinocerebellar ataxia presents to a neurology clinic. The neurologist documents progressive gait instability, dysarthria, and coordination deficits and orders targeted genetic testing for the ataxin 2 gene (ATXN2) to assess for CAG trinucleotide repeat expansions. A peripheral blood sample is collected in the outpatient phlebotomy lab or specialty genetics clinic and sent to a molecular diagnostics laboratory. In the lab, a molecular technologist or clinical laboratory scientist performs the technical assay (fragment analysis or PCR-based repeat-sizing) to detect expanded ATXN2 alleles. Results are reviewed by the laboratory director or molecular pathologist for analytic validity and released to the ordering neurologist. Typical sites of service include an outpatient genetics clinic, hospital outpatient laboratory, or reference molecular diagnostics laboratory. The specimen handling, analytical run, and result reporting follow clinical laboratory standards and may involve reflex testing or confirmatory methods if initial sizing is ambiguous. Clinical workflow steps: order entry by neurologist, specimen collection, accessioning, DNA extraction, PCR and sizing assay, data analysis by lab analyst, review by molecular pathologist, final report to clinician for patient counseling.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the professional interpretation component separate from the technical lab work when applicable in bundled billing environments. |